French Institute of Petroleum, Proteus and French National Center for Scientific Research | Date: 2015-06-12
The present invention relates to the expression and optimisation of enzymes involved in the breakdown of lignocellulosic biomass. The present invention specifically relates to variants of the exoglucanase 1 of Trichoderma reesei, as well as to the use of said variants with improved efficiency in methods for breaking down cellulose and for producing biofuel.
French Institute of Petroleum, Proteus and French National Center for Scientific Research | Date: 2015-06-12
The present invention relates to the expression and optimisation of enzymes involved in the breakdown of lignocellulosic biomass. The present invention specially relates to variants of the exoglucanase 2 of Trichoderma reesei, as well as to the use of said variants with improved efficiency in methods for breaking down cellulose and for producing biofuel.
News Article | May 10, 2017
Louvain-La-Neuve, Belgium, May 10, 2017 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today provides a trading update for the first quarter ending 31 March 2017. Olivier Legrain, Chief Executive Officer of IBA, commented: "We are pleased to have made good progress in this first quarter of 2017 and are on track to meet our growth targets. Dosimetry has seen a good recovery across all regions and is now positively contributing to our REBIT. Our production expansion and regionalization strategy to meet growing global demand continues to be rolled out and we are currently installing eight projects across the globe and getting ready to install another 17 internationally. "In Proton Therapy, however, several recent delays in project execution caused by customer building delays lead us to slightly adjust our full year guidance for 2017. While our guidance on revenue growth remains unchanged at around 15% to 20%, the project execution delays impact our revenue recognition and, to some extent, our operational leverage. Due to this, we revise our guidance on REBIT to between 10% and 12% for 2017, and around 13% for 2018. "We are confident in the strong prospects for IBA in 2017 and beyond due to our growth strategy, the significant market potential in proton therapy and our focus on maintaining the world's leading proton therapy offering." IBA reported the following segmental trends and news during the first quarter of 2017: Proton therapy's penetration of the radiation therapy market continues to grow due to increasing interest from the clinical community, affordability and technological advances. To keep ahead of and to lead this growth, IBA continues to scale up production capacity, including investment in a new superconducting synchrocyclotron assembly line (for Proteus®ONE*), and a new customer center, with an expected further combined CAPEX of about EUR 16 million, of which around EUR 10 million will be invested in 2017. The Company is also recruiting an additional 200 engineers and qualified staff, worldwide, through 2017. IBA has a high backlog of EUR 316 million and the sustainable revenue source from service and maintenance contracts now represents EUR 673 million of revenue over the next 10-15 years. IBA expects to achieve revenue growth of between 15% to 20% in 2017 and double digit thereafter. The Company expects its operating margin to be 10% to 12% in 2017, increasing to around 13% by 2018 and stabilizing at around 15% by 2020. IBA is planning to maintain a dividend payout ratio of 30%. This guidance is not only based upon the continued expected growth of the proton therapy market but also the balance between the economies of scale that we can achieve at a higher production rate. In addition, the growing importance of service revenue versus the increased demand driven by the equipment price tag reduction in the proton therapy market and our continued investment in R&D and software capabilities are anticipated to be contributing factors. In accordance with the Royal Decree of 14 November 2007, IBA indicates that this Trading Update has been prepared by the Chief Executive Officer (CEO) and the Chief Financial Officer (CFO). About IBA IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com *Proteus®ONE and Proteus®PLUS are brand names of Proteus 235 For further information, please contact:
News Article | May 10, 2017
Olivier Legrain, Chief Executive Officer d'IBA, a commenté: « Nous sommes heureux des progrès réalisés au premier trimestre 2017 et nous sommes sur la bonne voie pour atteindre nos objectifs de croissance. La Dosimétrie s'est fortement redressée dans toutes les régions et contribue positivement à notre REBIT. Notre stratégie d'augmentation de la capacité de production et de régionalisation, pour répondre à la demande mondiale croissante, se poursuit. Nous installons actuellement huit projets à travers le monde et nous nous préparons à en installer 17 autres. Cependant, en Protonthérapie, l'exécution de plusieurs projets a été différée en raison de retards de construction du bâtiment chez certains clients. Cela nous amène à ajuster légèrement notre prévision annuelle pour 2017. Alors que nos prévisions de croissance sur les revenus demeurent inchangées, entre 15% et 20%, les retards d'exécution de projets impactent la reconnaissance de nos revenus et, dans une certaine mesure, notre levier opérationnel. En conséquence, nous revoyons nos prévisions sur la marge REBIT à un taux entre 10% et 12% pour 2017, et environ 13% pour 2018. La pénétration de la protonthérapie sur le marché de la radiothérapie se poursuit grâce à l'intérêt grandissant de la communauté médicale, des prix abordables et des avancées technologiques. Afin de rester en avance et de mener cette croissance, IBA continue à accroître sa capacité de production, comprenant l'investissement dans la nouvelle ligne d'assemblage du synchrocyclotron du Proteus®ONE* et le centre destiné à l'accueil des clients, avec un investissement prévu d'environ EUR 16 millions, dont environ EUR 10 millions seront consentis en 2017. L'entreprise recrute également 200 ingénieurs et personnes qualifiées à travers le monde durant l'année 2017. IBA a un carnet de commandes élevé d'EUR 316 millions. La source de revenus durables des contrats de service et de maintenance représente actuellement EUR 673 millions de revenus sur les 10 à 15 prochaines années. IBA s'attend à une croissance des revenus entre 15% et 20% en 2017 et à maintenir ensuite une croissance à deux chiffres. Ces prévisions reposent sur la croissance continue attendue du marché de la protonthérapie mais également sur l'équilibre des économies d'échelle que l'entreprise peut réaliser grâce à une capacité de production accrue. De plus, l'importance croissante des revenus de services par rapport à la demande croissante résultant de la réduction des prix des équipements de protonthérapie sur le marché et nos investissements continus en R&D et en logiciels, devraient être des facteurs qui contribuent à la croissance. À propos d'IBA IBA (Ion Beam Applications S.A.) est une société de technologies médicales spécialisée dans le développement de solutions innovantes et intégrées pour le diagnostic et le traitement du cancer. IBA est le leader mondial en protonthérapie, considérée comme la forme de radiothérapie la plus avancée à ce jour. IBA adapte ses solutions de protonthérapie aux besoins des clients grâce à une gamme complète allant de centres de protonthérapie multisalles aux systèmes compacts, composés d'une salle de traitement. IBA développe également des solutions de dosimétrie pour la radiothérapie et la radiologie, ainsi que des accélérateurs de particules pour des applications médicales et industrielles. Avec son siège social situé en Belgique, IBA emploie plus de 1500 personnes dans le monde et installe ses systèmes partout dans le monde.
News Article | May 12, 2017
Ah, chitin … the cheap and plentiful substance, which occurs naturally in crustacean shells, has already been suggested for use in things like wound dressings, cheaper pharmaceuticals, and even proton-conducting transistors. Now, researchers from the National Taiwan Ocean University have found that when combined with silver, it could also be used to kill malaria-spreading mosquitoes. More specifically, the mixture has been proven effective at killing mosquito larvae, while they're still in the water. Led by Prof. Jiang-Shiou Hwang, the research team started by oven-drying and then crushing the shells of hydrothermal vent crabs, and then extracting chitin and other minerals from them. These were subsequently mixed with silver nitrate, resulting in a solution of chitin-enriched silver nanoparticles. That solution was later sprayed over six water reservoirs at India's National Institute of Communicable Disease Centre. It was found that even in low concentrations, the nanoparticles killed mosquito larvae and pupa very effectively. Hwang believes that this is due to the particles passing through the insects' outer cuticle and into individual cells. There, they "interfere with various physiological processes that are part of a mosquito's life cycle." As a side benefit, the solution was also found to inhibit the growth of dangerous bacteria such as Bacillus subtilis, Escherichia coli, Klebsiella pneumoniae and Proteus vulgaris. When tested on goldfish, however – which feed on mosquito larvae – it was found to have no harmful effect. A paper on the research was recently published in the journal Hydrobiologia.
News Article | May 11, 2017
Mosquitoes carry diseases such as malaria, dengue fever, yellow fever, the Zika virus and encephalitis. Despite more than 100 years of research on the subject, malaria remains a global health problem, especially in Sub-Saharan Africa and Asia. In 2013, the number of malaria cases was estimated at 198 million, and the number of malaria-related deaths at 548 000. According to the World Health Organization, one child dies every minute from malaria in Africa. Products such as organophosphates, insect growth regulators, microbial control agents and organic solutions are used in efforts to control mosquito populations and the spread of the disease. Hwang's team turned their attention to chitosan or chitin, a non-toxic natural substance that has been used in wound healing, as drug carriers and in manufacturing membrane water filters and biodegradable food package coating. Chitin is found in animal tissues, such as the exoskeletons of arthropods, bird beaks and insect eggs. It can easily be chemically changed, is quite strong and, because of its abundance in nature, is cost-effective to use. The research team first crushed and oven-dried the exoskeletons of a number of hydrothermal vent crabs (Xenograpsus testudinatus) before extracting the chitin and other minerals. The subsequent creamy-white filtrate was then mixed with silver nitrate (AgNO3) to obtain a brown-yellow solution of silver nanoparticles (AgNP). The solution was sprayed over six water reservoirs at the National Institute of Communicable Disease Centre in Coimbatore in India. Even in small concentrates it killed mosquito larvae and pupa quite effectively. It had the greatest effect during the early stages of the mosquito larvae's development. The solution was also tested in conjunction with freshwater goldfish (Carassiu auratus) that fed on mosquito larvae. The nanoparticle solution did not have any effect on the fish, indicating that it is an environmentally friendly and non-toxic product. It also inhibited the growth of disease-causing bacterial species such as Bacillus subtilis, Escherichia coli, Klebsiella pneumoniae and Proteus vulgaris. "This research highlighted that chitosan-fabricated silver nanoparticles are easy to produce, stable over time, and can be employed at low dosages to strongly reduce populations of the malaria vector, the Anopheles sundaicus mosquito, without detrimental effects on the predation of natural mosquito enemies, such as goldfishes," says Hwang. "It also effectively inhibits important bacterial pathogens." Hwang hypothesizes that the nanosized particles pass through the insect cuticles and into individual cells to then interfere with various physiological processes that are part of a mosquito's life cycle. More information: Kadarkarai Murugan et al, Chitosan-fabricated Ag nanoparticles and larvivorous fishes: a novel route to control the coastal malaria vector Anopheles sundaicus?, Hydrobiologia (2017). DOI: 10.1007/s10750-017-3196-1
French Institute of Petroleum, Proteus and French National Center for Scientific Research | Date: 2017-04-26
The present invention relates to the expression and optimisation of enzymes involved in the breakdown of lignocellulosic biomass. The present invention specifically relates to variants of the exoglucanase 2 of Trichoderma reesei, as well as to the use of said variants with improved efficiency in methods for breaking down cellulose and for producing biofuel.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: BIOTEC-1-2014 | Award Amount: 7.06M | Year: 2015
P4SB is about the utilization of the conceptual and material tools of contemporary Synthetic Biology to bring about the sustainable and environmentally friendly bioconversion of oil-based plastic waste into fully biodegradable counterparts by means of deeply engineered, whole-cell bacterial catalysts. These tools will be used to design tailor-made enzymes for the bio-depolymerization of PET (polyethylene terephthalate) and PU (polyurethane), but also for the custom design of a Pseudomonas putida Cell Factory capable of metabolizing the resulting monomers. Pseudomonas putida will undergo deep metabolic surgery to channel these diverse substrates efficiently into the production of polyhydroxyalkanoates (PHA) and derivatives. In addition, synthetic downstream processing modules based on the programmed non-lytic secretion of PHA will facilitate the release and recovery of the bioplastic from the bacterial biomass. These industry driven objectives will help to address the market need for novel routes to valorise the gigantic plastic waste streams in the European Union and beyond, with direct opportunities for SME partners of P4SB spanning the entire value chain from plastic waste via Synthetic Biology to biodegradable plastic. As a result we anticipate a completely biobased process reducing the environmental impact of plastic waste by establishing it as a novel bulk second generation carbon source for industrial biotechnology, while at the same time opening new opportunities for the European plastic recycling industry and helping to achieve the ambitious recycling targets set by the European Union for 2020.
Proteus, French Institute of Petroleum and French National Center for Scientific Research | Date: 2013-09-04
The invention relates to a polypeptide which has enhanced beta-glucosidase activity at a temperature of between about 30 C. and about 35 C.
Proteus | Date: 2011-01-21
The invention provides for methods of generating modified polynucleotide libraries by inserting and/or deleting at least three nucleotide residues in polynucleotide sequences. Theses methods may be used with other methods of gene modification such as gene shuffling. The invention further provides methods of directed molecular evolution using the modified polynucleotide libraries produced by these methods.